..Background and Purpose The results of a large prospective randomized trial have shown the efficacy of oral anticoagulation in the secondary prevention of major vascular events in patients with nonrheumatic atrial fibrillation (NRAF); less well established is the role of antiplatelet agents. The present study compared the effects of indobufen, a reversible inhibitor of platelet cyclooxygenase, with those of warfarin in this setting. Methods A total of 916 patients with NRAF and a recent (≤15 days) cerebral ischemic episode were admitted to this multicenter, randomized study, during which they were treated with either indobufen (100 or 200 mg BID) or warfarin (to obtain an international normalized ratio of 2.0 to 3.5) for 12 months. The two groups (462 on indobufen and 454 on warfarin) were well balanced in terms of their main baseline characteristics. The primary outcome of the study was the combined incidence of nonfatal stroke (including intracerebral bleeding), pulmonary or systemic embolism, nonfatal myocardial infarction, and vascular death. Results At the end of follow-up, the incidence of primary outcome events was 10.6% in the indobufen group (95% confidence interval, 7.7% to 13.5%) and 9.0% in the warfarin group (95% confidence interval, 6.3% to 11.8%), with no statistically significant difference between treatments. The frequency of noncerebral major bleeding complications was low: only four cases (0.9%) of gastrointestinal bleeding were observed, all of them in the warfarin group. Conclusions We conclude that, within the limitations of its design, this study may help the medical community in devising appropriate antithrombotic strategies for NRAF patients for whom oral anticoagulants are contraindicated or do not represent a feasible approach to treatment.
Indobufen versus Warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation / C., Morocutti; G., Amabile G; Mattioli, Anna Vittoria; for the SIFA, Investigator. - In: STROKE. - ISSN 0039-2499. - STAMPA. - 28(1997), pp. 1015-1021.
|Data di pubblicazione:||1997|
|Titolo:||Indobufen versus Warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation|
|Autore/i:||C., Morocutti; G., Amabile G; Mattioli, Anna Vittoria; for the SIFA, Investigator|
|Codice identificativo ISI:||WOS:A1997WZ26700025|
|Codice identificativo Scopus:||2-s2.0-8244245263|
|Codice identificativo Pubmed:||9158644|
|Citazione:||Indobufen versus Warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation / C., Morocutti; G., Amabile G; Mattioli, Anna Vittoria; for the SIFA, Investigator. - In: STROKE. - ISSN 0039-2499. - STAMPA. - 28(1997), pp. 1015-1021.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
|Indobufen Versus Warfarin in the Second...rheumatic Atrial Fibrillation | Stroke.pdf||articolo||Versione dell'editore (versione pubblicata)||Open Access Visualizza/Apri|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris